AUVYRON EDUCATION
CJC-1295 (No DAC) + Ipamorelin: Research Overview
CJC-1295 without DAC is a short-acting growth hormone–releasing hormone analog, while ipamorelin is a selective growth hormone secretagogue. Research has examined their effects on growth hormone signaling, IGF-1 and related physiological measures.
CJC-1295 (No DAC) + Ipamorelin Research Evidence
1. What CJC-1295 (No DAC) + Ipamorelin Is
1. What CJC-1295 (No DAC) + Ipamorelin Is
1. What CJC-1295 (No DAC) + Ipamorelin Is
CJC-1295 without DAC is a short-acting GHRH analog, while ipamorelin is a selective ghrelin receptor agonist. Research has examined their combined effects on growth hormone release, IGF-1 and related physiological measures.
2. Regulatory Status
1. What CJC-1295 (No DAC) + Ipamorelin Is
1. What CJC-1295 (No DAC) + Ipamorelin Is
CJC-1295 without DAC and ipamorelin are discussed primarily in research settings and are not FDA-approved medications. This page summarizes scientific information and does not provide treatment or human-use instructions.
3. Major Research Context
1. What CJC-1295 (No DAC) + Ipamorelin Is
4. Doses Evaluated in Research
Published research has examined growth hormone secretagogues and GHRH analogs in relation to GH pulsatility, IGF-1 response, endocrine signaling and related physiological measures.
4. Doses Evaluated in Research
4. Doses Evaluated in Research
4. Doses Evaluated in Research
Human ipamorelin research evaluated 15-minute intravenous infusions at 4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg. Separate human studies of long-acting CJC-1295 evaluated doses of 30 and 60 mcg/kg.
These studies did not evaluate the exact CJC-1295 (No DAC) and ipamorelin combination. The amounts describe published research methodology and are not dosing recommendations.
5. Reported Outcomes
4. Doses Evaluated in Research
5. Reported Outcomes
Research has reported changes in growth hormone signaling, IGF-1 levels and related endocrine markers. Outcomes vary according to the compound, dose, duration, study design and participant characteristics.
6. Safety Findings
4. Doses Evaluated in Research
5. Reported Outcomes
Reported effects associated with growth hormone secretagogue activity have included fluid retention, tingling, appetite changes and alterations in glucose-related measures. Findings depend on the compound, dose and duration studied.
Published Research Highlights
1. Mechanistic Background
CJC-1295 without DAC has been studied as a short-acting GHRH analog, while ipamorelin has been studied as a selective secretagogue acting through the ghrelin receptor pathway.
2. Growth Hormone Signaling
Research has focused on stimulation of endogenous growth hormone release and its downstream relationship with IGF-1 and related physiological markers.
3. IGF-1 Response
Studies and mechanistic literature have examined changes in IGF-1 as an indirect marker of growth hormone pathway activity. Responses vary by compound, duration and research design.
4. Body Composition Interest
Research interest has included the relationship between GH-pathway stimulation, lean-mass measures and fat-metabolism–related outcomes, although findings depend on the population and study context.
5. Recovery and Sleep Interest
Growth hormone secretagogues have also been studied in relation to recovery physiology and sleep-associated patterns of growth hormone release.
6. Research Limitations
Interpretation should depend on the specific compound, dose, duration, comparator and study population. Evidence for the combined use of CJC-1295 without DAC and ipamorelin remains limited.
Scientific References & Research Disclaimer
1. Research Sources
This guide summarizes peer-reviewed endocrine research, mechanistic studies and published scientific literature related to GHRH analogs and growth hormone secretagogues.
2. Primary Publications
Key publications include human CJC-1295 studies published in The Journal of Clinical Endocrinology & Metabolism and a human ipamorelin pharmacokinetic and pharmacodynamic study published in Pharmaceutical Research.
The CJC-1295 studies evaluated the long-acting DAC form, while the ipamorelin study evaluated ipamorelin separately. They did not examine the exact CJC-1295 (No DAC) + ipamorelin combination.
3. Educational Use
CJC-1295 and ipamorelin are not FDA-approved medications, and the exact CJC-1295 (No DAC) + ipamorelin combination has not been evaluated or authorized for medical use.
This content is provided for educational and research-information purposes only. It is not medical advice, dosing guidance or instructions for human use.
4. Research Use Only
For Research Use Only. Not for Human Consumption.
Quality. Innovation. Excellence.
This website uses cookies.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.